Welcome to MutualFunds.com. Please help us personalize your experience.
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
The company reported earnings of $1.835 billion, or $1.79 per share, up from $55.4 million, or 6 cents per share, last year. Analysts expected to see EPS of 7 cents.
Revenue increased to $6.85 billion from $6.60 billion last year. Analysts expected to see revenue of $6.80 billion.
Looking ahead, RAD expects to see FY2016 EPS between 19 cents and 27 cents.
Like other drug companies, Rite Aid is expanding its pharmacy and wellness business to boost sales. During the quarter, prescription sales grew 3.5%; this business segment accounted for 68.1% of total sales.
|RPMGX||T. Rowe Price Mid-Cap Growth||2.80%|
|PRHSX||T. Rowe Price Health Sciences||2.31%|
|NAESX||Vanguard Small Cap Index||1.81%|
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.
Receive email updates about best performers, news, CE accredited webcasts and more.
Check out our Q&A with Brian Spinelli, Chair of Investment Committee and Senior...
Check out our Q&A with Deron McCoy, CIO of Signature Estate & Investment...